Last updated: February 26, 2026
What is NDC 00904-6888?
NDC 00904-6888 identifies a specific drug product registered in the United States under the National Drug Code system. Based on the latest available data, this NDC corresponds to Dilesse (ranibizumab), a biosimilar or generic version of Lucentis (ranibizumab), used for treating neovascular age-related macular degeneration, diabetic macular edema, and other retinal vascular disorders.
Market Overview
Product Class and Therapeutic Area
- Class: Ranibizumab biosimilars/generics
- Indications: Wet age-related macular degeneration, diabetic retinopathy, retinal vein occlusion
- Mechanism: Inhibits vascular endothelial growth factor A (VEGF-A)
Market Size
The global market for intravitreal anti-VEGF products was valued at approximately USD 7.2 billion in 2022, with a compound annual growth rate (CAGR) of 4.5% projected through 2027 (source [1]).
The U.S. market accounts for roughly 40% of this global figure, with a valuation near USD 2.9 billion in 2022. This segment is driven by the high prevalence of age-related macular degeneration (AMD) and diabetic retinopathy.
Competitive Landscape
- Existing Products: Lucentis (Genentech), Eylea (Bayer), Beovu (Boehringer Ingelheim)
- Biosimitars/Gens: Several biosimilars in development or approved, aiming to lower treatment costs
- Pricing Dynamics: Brand-name ranibizumab sold for USD 2,000–USD 2,200 per injection
Regulatory Status
- Received FDA approval for use as a biosimilar in the U.S.
- Market entry depends on payer coverage, physician acceptance, and institutional formularies
Price Projections
Current List Prices and Discount Expectations
- When first introduced, biosimilar ranibizumab products are expected to command a list price approximately 20–30% lower than branded Lucentis.
- Estimated initial list price: USD 1,400–USD 1,760 per injection.
- Contracted prices through pharmacy benefit managers (PBMs) and hospitals may reduce net acquisition costs by an additional 10–15%.
Market Penetration and Price Erosion Trends
- Within the first 12–18 months post-launch, biosimilar products typically capture 25–35% of the market share, driven by competitive pricing and formulary inclusions.
- Price erosion is expected to increase to 40–50% within 3 years, as more biosimilar competitors enter the market and payers negotiate further discounts.
Revenue Projections (2023–2027)
| Year |
Estimated Market Share |
Average Price per Injection |
Estimated Revenue (USD millions) |
| 2023 |
15% |
USD 1,400 |
USD 150 |
| 2024 |
25% |
USD 1,325 |
USD 300 |
| 2025 |
35% |
USD 1,250 |
USD 450 |
| 2026 |
45% |
USD 1,200 |
USD 600 |
| 2027 |
50% |
USD 1,150 |
USD 700 |
(Note: Estimates assume steady adoption, delayed formulary access, and incremental price declines)
Key Market Drivers and Barriers
Drivers
- Cost savings for payers and providers
- Objectively high clinical efficacy
- Growing prevalence of retinal diseases
Barriers
- Physician familiarity with branded products
- Payer reluctance to switch established therapies without substantial evidence
- Manufacturing and biosimilarity regulatory hurdles
Regulatory and Policy Impact
- Recent FDA approvals set the stage for increased biosimilar competition.
- CMS and private payers' policies favor lower-cost biosimilars, facilitating market penetration.
- Patent litigation and exclusivity periods may delay biosimilar uptake, targeting mid-2024 for USD 1–2 billion revenue potential in U.S.
Strategic Considerations
- Partnerships with large pharmaceutical firms to improve market access
- Focused clinical data to demonstrate biosimilarity efficacy and safety
- Early formulary inclusion can substantially influence market share and price trajectory
Key Takeaways
- NDC 00904-6888 corresponds to a ranibizumab biosimilar targeting the lucrative AMD and diabetic retinopathy segments.
- The product is positioned to capture significant share through aggressive pricing, starting at approximately 20–30% price discount.
- Market volume is expected to grow 4–5% annually, with biosimilars capturing a larger share by 2025.
- Prices are projected to decline 15–20% annually as competition intensifies, with potential to reduce treatment costs by up to 50% relative to branded therapy within three years.
- Market entry strategies should focus on early formulary access, clinical evidence, and payer engagement.
FAQs
1. When will NDC 00904-6888 likely achieve significant market share?
Expected between 18-24 months post-launch, as payers and providers adopt biosimilars.
2. What factors could accelerate price reductions?
Increased biosimilar approvals, early formulary acceptance, and aggressive contracting.
3. Will biosimilar prices stabilize or continue decreasing?
Prices typically continue to decrease over initial years due to competition, with stabilization possible beyond 2026.
4. How does biosimilar acceptance vary across regions?
Higher in the U.S. due to advanced payer policies; slower in regions with entrenched brand loyalty or regulatory delays.
5. What are the main barriers to biosimilar adoption?
Physician skepticism, limited familiarity, and negotiations with payers delaying formulary inclusion.
References
[1] MarketWatch. (2023). “Global Anti-VEGF Market Size, Share & Trends.”
[2] IQVIA. (2022). "U.S. Ophthalmic Drug Market Report."
[3] FDA. (2022). "Biosimilar Product Approvals and Guidance."
[4] EvaluatePharma. (2022). "Biosimilar Insulin & Ophthalmology Outlooks."
